Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11131010 | 0.88 | ALDH1A1 (0.48) | GAAALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL5390124 | 0.85 | GAA (0.53) | GAATSHRALDH1A1POLBKDM4E | |
| SCHEMBL8998797 | 0.83 | KDM4E (0.49) | GAATSHRALDH1A1HPGDPOLB | |
| SCHEMBL11049685 | 0.83 | ALDH1A1 (0.50) | GAATSHRALDH1A1HPGDPOLB | |
| SCHEMBL23748611 | 0.82 | HTT (0.41) | TSHRALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL28618808 | 0.82 | HTT (0.41) | TSHRALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL5376589 | 0.81 | POLB (0.46) | GAATSHRALDH1A1HPGDPOLB | |
| SCHEMBL11015471 | 0.81 | KAT6A (0.50) | GAATSHRALDH1A1POLBKDM4E | |
| SCHEMBL27726630 | 0.81 | BLM (0.47) | GAATSHRALDH1A1POLBKDM4E | |
| SCHEMBL686832 | 0.80 | KDM4E (0.57) | TSHRALDH1A1HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0729953-A2 | A process for producing a 2-substituted-3,4-fused heterocyclic benzoic acid | ROHM AND HAAS COMPANY (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0602794-A2 | Insecticidal N'-substituted-N, N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1994-06-22 | — | — | EP | claimed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2125797-B1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-8592460-B2 | Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-26 | — | — | US | disclosed |
| CN-101627034-B | amino-pyridine derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD | 2013-05-15 | — | — | CN | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2438078-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| WO-2008114157-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-25 | — | — | WO | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| EP-0729934-A2 | A process for producing a 3-alkoxy-2-(substituted)benzoic acid or an ester thereof | ROHM AND HAAS COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0729953-A2 | A process for producing a 2-substituted-3,4-fused heterocyclic benzoic acid | ROHM AND HAAS COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0471277-B1 | Silanol compounds, polymerizable monomers and polymers having mesogenic groups | SAGAMI CHEM RES (JP) | 1995-11-15 | — | — | EP | disclosed |
| US-5329034-A | Silanol compounds, polymerizable monomers and polymers having mesogenic groups | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-07-12 | — | — | US | disclosed |
| EP-0602794-A2 | Insecticidal N'-substituted-N, N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1994-06-22 | — | — | EP | disclosed |
| EP-0471277-A2 | Silanol compounds, polymerizable monomers and polymers having mesogenic groups | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | GAA 668/4885TSHR 2801/4885ALDH1A1 3407/4885 |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | GAA 402/4885TSHR 3684/4885ALDH1A1 4309/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | GAA 236/4885TSHR 2562/4885ALDH1A1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.